Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Caloric Restriction in Obesity and Type 2 Diabetes (CRESO2)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Mario Negri Institute for Pharmacological Research
Sponsor:
Collaborator:
Istituto Superiore di Sanità
Information provided by (Responsible Party):
Mario Negri Institute for Pharmacological Research
ClinicalTrials.gov Identifier:
NCT01930136
First received: August 23, 2013
Last updated: September 24, 2014
Last verified: September 2014

August 23, 2013
September 24, 2014
May 2013
February 2016   (final data collection date for primary outcome measure)
The percent change in glomerular filtration rate (GFR) at month 6 versus baseline and the rate of GFR decline from month 6 to study end [ Time Frame: At baseline, 6, 12 and 24 month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01930136 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Caloric Restriction in Obesity and Type 2 Diabetes
LONG-TERM EFFECTS OF CALORIC RESTRICTION ON METABOLIC, RENAL AND RETINAL HEALTH IN SUBJECTS AFFECTED BY OBESITY AND TYPE 2 DIABETES

The study investigates whether a long-term 25% caloric restriction can prevent onset and/or progression of renal function deterioration, retinal involvement and cardiovascular complications in overweight/obese type 2 diabetic patients, trough the amelioration of concomitant metabolic abnormalities such as visceral obesity, insulin resistance, dyslipidemia, hypertension and inflammation.

The main aim of the study is therefore to evaluate the role of calorie restriction (CR) on subjects at risk of nephropathy. Secondary aims are to better understand the relationship between CR and the following aspects: renal disease and its associated metabolic abnormalities, retinopathy and cardiovascular complications, quality of life and treatment cost.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Type 2 Diabetes
  • Obesity
  • Behavioral: Calorie restriction (25%)
  • Behavioral: Ad libitum health diet
  • Experimental: Calorie restriction (25%)
    CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
    Intervention: Behavioral: Calorie restriction (25%)
  • Active Comparator: Ad libitum health diet
    Intervention: Behavioral: Ad libitum health diet
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
June 2016
February 2016   (final data collection date for primary outcome measure)

Inclusion Criteria

  • Age >40 years;
  • Type 2 diabetes (ADA criteria);
  • UAE <300 mg/24h;
  • Body mass index (BMI)>27kg/m2;
  • Serum creatinine < 1.2 mg/dL;
  • No major changes in calorie, protein and sodium intake in the last 6 mos;
  • No major changes in concomitant treatments with blood pressure, glucose or lipid lowering agents since 6 and 3 months respectively;
  • Patients legally able to give written informed consent to the trial (signed and dated by the patient);
  • Written informed consent.

Exclusion Criteria

  • Concomitant non-diabetic renal disease or ischemic kidney disease;
  • Primary or immune-mediated renal disease;
  • Urinary tract obstruction or infection;
  • Treatment with steroids and/or non-steroid anti-inflammatory agents;
  • Treatment with thiazide or loop diuretics that, on the basis of the Investigator's judgment, might sustain hypovolemia and/or sodium depletion (with secondary kidney hypoperfusion/hypofiltration);
  • Hearth failure and/or hemodynamically significant left ventricular systolic dysfunction, cirrhosis, uncontrolled hyperglycemia resulting in glycosuria, hyper/hyponatremia of any cause;
  • Previous surgical procedures for weight loss;
  • Previous episodes of depression, or suicide attempts;
  • Chronic abuse of alcohol and drugs;
  • Pregnancy, ineffective contraception or peri-menopausal age;
  • Cancer or any chronic disease that might affect the completion of the study;
  • Chronic obstructive pulmonary disease (COPD) in treatment with positive airway pressure;
  • Unwillingness or inability to adhere to CR intervention over the entire 24-months intervention period;
  • Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;
  • Evidence of an uncooperative attitude;
  • Any evidence that patient will not be able to complete the trial follow-up;
  • Inability to fully understand the potential risks and benefits of the study.
Both
40 Years and older
No
Contact: Piero Ruggenenti, MD 0039 035 45351 piero.ruggenenti@marionegri.it
Italy
 
NCT01930136
CRESO 2
No
Mario Negri Institute for Pharmacological Research
Mario Negri Institute for Pharmacological Research
Istituto Superiore di Sanità
Not Provided
Mario Negri Institute for Pharmacological Research
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP